Skip to main content

Table 2 Characteristics of all reports for the 58 antidepressant drugs of interest in VigiBase® (n = 1,027,405)

From: Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database

Characteristics N %
Age group
 5-17a 20,174 1.96
 18–44 252,790 24.60
 45–64 281,177 27.37
 65–74 94,779 9.23
  ≥ 75 79,894 7.78
 Unknown 298,591 29.06
Sex group
 Male 309,665 30.14
 Female 665,950 64.82
 Unknown 51,790 5.04
WHO reporting area
 Africa 3507 0.34
 Americas
  United States 594,543 57.87
  Canada 44,079 4.29
  Other countries 5549 0.54
 Asia
  China 9827 0.96
  India 8284 0.81
  Japan 7722 0.75
  Singapore 1012 0.10
  South Korea 15,919 1.55
  Other countries 5863 0.57
Europe
  France 45,142 4.39
  Germany 36,334 3.54
  Italy 16,180 1.57
  United Kingdom 99,131 9.65
  Other countries 97,238 9.46
 Oceania
  Australia 30,210 2.94
  New Zealand 6865 0.67
Notifier type
  Physicians 310,728 30.24
  Pharmacists 65,062 6.33
  Other health professionals 84,365 8.21
  Patients 238,572 23.22
  Hospitals 38,922 3.79
  Lawyers 13,372 1.30
  Drugs companies 6470 0.63
  Others 124,913 12.16
  Unknown 145,001 14.11
Serious cases
  Yes 385,788 37.55
  No 300,879 29.29
  Unknown 340,738 33.16
  1. WHO, World Health Organization aQuality of reports under the age of five was uncertain and they were thus excluded